Owing to the sustained and focused efforts, our antibiotic discovery team has been able to evolve a rich pipeline of candidate drugs which are either approved or at various stages of clinical development. All our novel antibiotics (WCK 771, WCK 2349, WCK 4873, WCK 4282, WCK 5222 and WCK 6777) are designed to address current and future unmet needs in the management of community-acquired and/or hospital-acquired infections caused by resistant bacterial pathogens. Since these drugs target several CDC/WHO/FDA listed priority pathogens, all of them have earned qualified infectious disease product designation (QIDP) by US FDA.
Of these novel antibiotics, WCK 771 (levonadifloxacin, IV) and WCK 2349 (alalevonadifloxacin, Oral) have been approved in India for the treatment of acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot infections (DFI) and concurrent bacteremia. WCK 771 is an arginine salt of levonadifloxacin, a broad-spectrum benzoquinolizine sub-class of fluoroquinolone with a potent activity against Staphylococcus aureus including MRSA, quinolone-resistant S. aureus and vancomycin-non-susceptible strains (VISA and VRSA). In India, the intravenous formulation of WCK 771 has received marketing approval under the brand name of EMROK. WCK 2349 is mesylate salt of alanine ester prodrug of WCK 771 with > 90% oral bioavailability compared to intravenous WCK 771. The prodrug has been designed to enable a seamless oral switch therapy facilitating early discharge of patients from hospitals as well as for the management of infections caused by community MRSA. In India, the oral formulation of WCK 2349 is marketed under the brand name EMROK O.